Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

news image

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

news image

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

news image

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

news image

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More
news image

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More
news image

MedTech, Medical

PATENT AWARDED FOR PRIMARY TEMPLATE-DIRECTED AMPLIFICATION, FURTHER STRENGTHENING BIOSKRYB GENOMICS’ CORE TECHNOLOGIES

Businesswire | August 21, 2023

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children&rs...

Read More
news image

Industry Outlook

MAGENTA THERAPEUTICS AND DIANTHUS THERAPEUTICS ANNOUNCE MERGER AGREEMENT

Globenewswire | May 04, 2023

Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upo...

Read More
news image

Industry Outlook

IONPATH EXPANDS PARTNERSHIPS FOR RAPIDLY DELIVER NOVEL INSIGHTS UTILIZING COMPANY'S HIGH-DEFINITION SPATIAL PROTEOMICS PLATFORM

IONpath, Inc. | August 27, 2021

Ionpath, Inc., the leader in high-definition spatial proteomics, today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology. Through this new program, customers can benefit from in-depth immune profiling and spatial analysis performed with the company's 30-marker Checkpoint Panel on its MIBIscope™ System. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us